Literature DB >> 18638702

The globalization of ayahuasca: harm reduction or benefit maximization?

Kenneth W Tupper1.   

Abstract

Ayahuasca is a tea made from two plants native to the Amazon, Banisteriopsis caapi and Psychotria viridis, which, respectively, contain the psychoactive chemicals harmala alkaloids and dimethyltryptamine. The tea has been used by indigenous peoples in countries such as Brazil, Ecuador and Peru for medicinal, spiritual and cultural purposes since pre-Columbian times. In the 20th century, ayahuasca spread beyond its native habitat and has been incorporated into syncretistic practices that are being adopted by non-indigenous peoples in modern Western contexts. Ayahuasca's globalization in the past few decades has led to a number of legal cases which pit religious freedom against national drug control laws. This paper explores some of the philosophical and policy implications of contemporary ayahuasca use. It addresses the issue of the social construction of ayahuasca as a medicine, a sacrament and a "plant teacher." Issues of harm reduction with respect to ayahuasca use are explored, but so too is the corollary notion of "benefit maximization."

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18638702     DOI: 10.1016/j.drugpo.2006.11.001

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  27 in total

1.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Authors:  Marc G Blainey
Journal:  J Relig Health       Date:  2015-02

3.  An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders.

Authors:  Marika Renelli; Jenna Fletcher; Kenneth W Tupper; Natasha Files; Anya Loizaga-Velder; Adele Lafrance
Journal:  Eat Weight Disord       Date:  2018-11-24       Impact factor: 4.652

4.  Pharmacology of ayahuasca administered in two repeated doses.

Authors:  Rafael G Dos Santos; Eva Grasa; Marta Valle; Maria Rosa Ballester; José Carlos Bouso; Josep F Nomdedéu; Rosa Homs; Manel J Barbanoj; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2011-08-13       Impact factor: 4.530

5.  Psychoactive substances and the political ecology of mental distress.

Authors:  Sunil K Aggarwal; Gregory T Carter; Craig Zumbrunnen; Richard Morrill; Mark Sullivan; Jonathan D Mayer
Journal:  Harm Reduct J       Date:  2012-01-18

6.  Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities.

Authors:  Joaquim Soler; Matilde Elices; Alba Franquesa; Steven Barker; Pablo Friedlander; Amanda Feilding; Juan C Pascual; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

Review 7.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

8.  Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.

Authors:  Caroline Dorsen; Joseph Palamar; Michele G Shedlin
Journal:  Addict Res Theory       Date:  2018-03-30

9.  Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.

Authors:  Brian Rush; Olivia Marcus; Sara García; Anja Loizaga-Velder; Gabriel Loewinger; Ariane Spitalier; Fernando Mendive
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

10.  Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study.

Authors:  José Carlos Bouso; Débora González; Sabela Fondevila; Marta Cutchet; Xavier Fernández; Paulo César Ribeiro Barbosa; Miguel Ángel Alcázar-Córcoles; Wladimyr Sena Araújo; Manel J Barbanoj; Josep Maria Fábregas; Jordi Riba
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.